Ultragenyx Pharmaceutical (NASDAQ:RARE) PT Lowered to $60.00 at Evercore ISI


Pharmaceutical Ultragenyx (NASDAQ: RAREGet a rating) had its target price lowered by Evercore ISI to $60.00 in a research note released on Tuesday morning, Target Stock Advisor reports.

Other stock analysts have also published research reports on the company. Citigroup reduced its target price on Ultragenyx Pharmaceutical from $146.00 to $142.00 in a Wednesday, August 3 research note. Barclays lowered its price target on shares of Ultragenyx Pharmaceutical from $141.00 to $105.00 in a Friday July 29 research note. Cowen cut his target price on shares of Ultragenyx Pharmaceutical from $124.00 to $99.00 in a Friday, May 6 report. Goldman Sachs Group cut its price target on Ultragenyx Pharmaceutical from $139.00 to $101.00 and set a neutral rating for the company in a Tuesday, May 24 research note. Finally, Stifel Nicolaus lowered his price target on Ultragenyx Pharmaceutical from $176.00 to $142.00 and set a buy rating on the stock in a Friday July 1 report. Two equity research analysts rated the stock with a sell rating, one gave the company a hold rating and seven gave the company a buy rating. Based on data from MarketBeat, the company has a Moderate Buy consensus rating and a consensus target price of $108.62.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ: RARE opened at $51.57 on Tuesday. The company has a market capitalization of $3.61 billion, a P/E ratio of -7.05 and a beta of 1.21. The company’s 50-day moving average is $55.98 and its 200-day moving average is $62.84. Ultragenyx Pharmaceutical has a 1 year low of $45.20 and a 1 year high of $104.38.

Pharmaceutical Ultragenyx (NASDAQ: RAREGet a rating) last reported quarterly earnings data on Thursday, July 28. The biopharmaceutical company reported ($2.26) EPS for the quarter, missing the consensus estimate of ($1.72) by ($0.54). The company posted revenue of $89.34 million in the quarter, compared to $87.33 million expected by analysts. Ultragenyx Pharmaceutical had a negative net margin of 151.34% and a negative return on equity of 60.76%. The company’s revenue for the quarter increased by 2.7% compared to the same quarter last year. During the same period of the previous year, the company had made earnings per share of ($1.45). On average, analysts expect Ultranyx Pharmaceutical to post EPS of -7.79 for the current year.

Institutional entries and exits

Hedge funds have recently increased or reduced their stakes in the company. IndexIQ Advisors LLC acquired a new stake in shares of Ultragenyx Pharmaceutical in the first quarter worth approximately $44,000. Lazard Asset Management LLC increased its stake in Ultragenyx Pharmaceutical by 36.6% in the 1st quarter. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company valued at $64,000 after acquiring an additional 240 shares in the last quarter. Alpha Paradigm Partners LLC bought a new position in Ultragenyx Pharmaceutical in Q4 for a value of approximately $113,000. Harbor Capital Advisors Inc. acquired a new position in shares of Ultragenyx Pharmaceutical during Q1 worth approximately $169,000. Finally, Essex Investment Management Co. LLC increased its position in shares of Ultragenyx Pharmaceutical by 14.9% in the first quarter. Essex Investment Management Co. LLC now owns 2,682 shares of the biopharmaceutical company valued at $195,000 after buying 348 additional shares last quarter. 97.49% of the shares are held by institutional investors and hedge funds.

About Ultranyx Pharmaceutical

(Get a rating)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe and internationally . Its biologics include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with mucopolysaccharidosis VII; Dojolvi for the treatment of long chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Further reading

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ: RARE)



Get news and reviews for Ultragenyx Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com’s free daily email newsletter.